Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27
A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tumor and blood samples from postmenopausal women with primary breast cancer enrolled on clinical trial CAN-NCIC-MA27.
研究概览
详细说明
OBJECTIVES:
Primary
- To identify genetic variation, as measured by single nucleotide polymorphisms, that is associated with musculoskeletal adverse events in specimens from postmenopausal women with hormone receptor-positive primary breast cancer receiving adjuvant aromatase inhibitors and enrolled on clinical trial CAN-NCIC-MA27.
OUTLINE: This is a multicenter study.
DNA from tumor tissue and blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
研究类型
注册 (预期的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed invasive breast cancer
- Complete resection of primary tumor
- Stage I-III (T1-3, N0-3, M0) disease
- Enrolled in clinical trial CAN-NCIC-MA27.
- No locally recurrent or metastatic breast cancer
Hormone receptor status:
- Estrogen receptor- or progesterone receptor-positive disease
PATIENT CHARACTERISTICS:
Postmenopausal status, defined as one of the following:
- At least 60 years old
- Age 45-59 years with spontaneous cessation of menses for > 12 months prior to chemotherapy or study randomization
- Age 45-59 years with cessation of menses for < 12 months or secondary to hysterectomy AND a follicle-stimulating hormone (FSH) level in the postmenopausal range (or > 34.4 IU/L)
- Age 45-59 years on hormone replacement therapy (HRT) and discontinued HRT at diagnosis of breast cancer AND FSH level in the postmenopausal range (or > 34.4 IU/L)
- Bilateral oophorectomy
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Single group
DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Genetic variation associated with musculoskeletal adverse events
大体时间:Up to 2 years
|
Up to 2 years
|
合作者和调查者
调查人员
- 学习椅:James Ingle, MD、Mayo Clinic
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
多态性分析的临床试验
-
Hvidovre University HospitalElsassFonden终止